Edwin M. Posadas, MD | Authors

March 17, 2021

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

September 15, 2016

Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.